Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS

NCT07743268 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: nL-TARDB-006

Sponsor

n-Lorem Foundation

Collaborators

[object Object]
[object Object]